JW Pharmaceutical said that it has launched Fuenpera, an influenza treatment in an intravenous (IV) injection, and has begun full-scale marketing activities.

“Unlike oseltamivir, which patients have to receive orally for five days, Fuenpera uses peramivir hydrate as its main substance that treats the flu with a single IV injection,” the company said. “Hospitals can use the treatment for influenza A or B virus infection in adults and children over two years of age.”

Fuenpera is the first premix flu treatment in the form of an IV bag in Korea that mixed peramivir hydrate and physiological saline, the company added.

The company's treatment greatly increased convenience for hospitals as previous influenza injections in a vial formulation had to undergo mixing with the basic fluid.

Also, the company has applied easy-cut technology, which allows hospitals to open only the lower part of the aluminum packaging and connect the infusion set.

“Reflecting the needs of the medical field, we have developed an influenza IV treatment that can relieve discomfort in the drug mixing process,” a company official said. “The company will expand its market share through marketing emphasizing the features of products that enhance the convenience of dispensing for patient treatment.”

The official stressed that JW Life Sciences would be in charge of the production of Fuenpera.